Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer

Tissue Antigens

Volumn 70, Issue 3, 2007, Pages 205-213

  Gamzatova, Z ^a,b   Villabona, L ^a   Van Der Zanden, H ^c   Haasnoot, G W ^c   Andersson, E ^a   Kiessling, R ^a   Seliger, B ^d   Kanter, L ^a   Dalianis, T ^a   Bergfeldt, K ^a   Masucci, G V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Haplotypes; HLA A2; Ovarian cancer; Serous adenocarcinoma of the ovary

Indexed keywords

HLA A ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DONOR; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; NETHERLANDS; OVARY CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 34547135674     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00875.x     Document Type: Article

References (42)

1. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 2002 : 25 : 189 201.
2. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999 : 93 : 21 4.
3. Townsend ARM, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985 : 42 : 457.
4. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997 : 24 : 293 312.
5. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJ, Kitchener HC, Stern PL. Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res 2003 : 63 : 400 3.
6. Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 1998 : 25 : 329 37.
7. Lu CC, Chen JC, Jin YT, Yang HB, Chan SH, Tsai ST. Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. Int J Cancer 2003 : 103 : 745 51.
8. De Petris L, Bergfeldt K, Hising C et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 2004 : 21 : 49 52.
9. Benedet JL, Bender H, Jones H III., Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000 : 70 : 209 62.
10. Tavassoli F, Devilee P. Tumours of the breast and female genital organs : ed IARC Press, Lyon, 2003.
11. Schipper RF, D'Amaro J, de Lange P, Schreuder GM, van Rood JJ, Oudshoorn M. Validation of haplotype frequency estimation methods. Hum Immunol 1998 : 59 : 518 23.
12. Schipper RF, D'Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshoorn M. HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 1997 : 52 : 54 71.
13. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994 : 43 : 18 27.
14. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955 : 19 : 251 3.
15. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1956 : 20 : 309 11.
16. Iaffaioli RV, Maio M, Ruggiero G et al. HLA and prognostic factors in primary breast cancer. Int J Cancer 1985 : 35 : 581 5.
17. So T, Takenoyama M, Sugaya M et al. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 2001 : 32 : 39 46.
18. Biswal BM, Kumar R, Julka PK, Sharma U, Vaidya MC. Human leucocytic antigens (HLA) in breast cancer. Indian J Med Sci 1998 : 52 : 177 83.
19. Chan SH. Immunogenetics of nasopharyngeal carcinoma - position in 1980. Ann Acad Med Singapore 1980 : 9 : 296 9.
20. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 1998 : 12 : 455 62.
21. Gamzatova Z, Villabona L, Dahlgren L et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 2006 : 103 : 145 50.
22. Bocchia M, Wentworth PA, Southwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995 : 85 : 2680 4.
23. Clark RE, Hermans J, Madrigal A et al. HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. Br J Haematol 2001 : 114 : 36 41.
24. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000 : 55 : 140 8.
25. Posthuma EF, Falkenburg JH, Apperley JF et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999 : 93 : 3863 5.
26. Markman M, Braine HG, Bias WB, Karp JE. Human histocompatibility antigens and survival in acute myelocytic leukemia. Cancer 1984 : 53 : 1515 7.
27. Illeni MT, Pasquali M, La Monica G, Bohm S, Rovini D, Di Re E. HLA antigens in ovarian adenocarcinoma patients. Eur J Gynaecol Oncol 1985 : 6 : 121 5.
28. Luongo V, Pirozzi G, Caraco C et al. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 2004 : 64 : 84 7.
29. Gourley C, Thornton C, Massie C et al. Is there a relationship between HLA type and prognostic factors in breast cancer? Anticancer Res 2003 : 23 : 633 8.
30. Fensterle J, Trefzer U, Berger T, Andersen MH, Ugurel S, Becker JC. HLA-B8 association with late-stage melanoma-an immunological lesson? BMC Med 2006 : 4 : 5.
31. Kubler K, Arndt PF, Wardelmann E, Krebs D, Kuhn W, van der Ven K. HLA-class II haplotype associations with ovarian cancer. Int J Cancer 2006 : 119 : 2980 5.
32. Fallingborg J, Ambrosius Christensen L, Grunnet N. HLA antigens in a family with Behcet's syndrome. Acta Med Scand 1986 : 220 : 375 8.
33. Runge LA, Davey FR, Goldberg J, Boyd PR. The inheritance of Felty's syndrome in a family with several affected members. J Rheumatol 1986 : 13 : 39 42.
34. Cudworth AG, Wolf E, Gorsuch AN, Festenstein H. A new look at HLA genetics with particular reference to type-1 diabetes. Lancet 1979 : 2 : 389 91.
35. Best CL, Pudney J, Welch WR, Burger N, Hill JA. Localization and characterization of white blood cell populations within the human ovary throughout the menstrual cycle and menopause. Hum Reprod 1996 : 11 : 790 7.
36. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 : 348 : 203 13.
37. Norell H, Carlsten M, Ohlum T et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 2006 : 66 : 6387 94.
38. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 1995 : 3 : 801 9.
39. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995 : 268 : 405 8.
40. Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol 2005 : 35 : 10 15.
41. Snyder GA, Brooks AG, Sun PD. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci U S A 1999 : 96 : 3864 9.
42. Le Bouteiller P, Barakonyi A, Giustiniani J et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A 2002 : 99 : 16963 8.